Capricor Therapeutics Inc
Capricor Therapeutics Inc (CAPR) Straddle
CAPR straddle scan found 159 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 77.8%.
Read more
Trading a CAPR straddle lets you take a pure volatility position on Capricor Therapeutics Inc without committing to a direction. Capricor Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate CAPR straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on CAPR profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Capricor Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the CAPR straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19.
It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the CAPR straddle is the cleanest expression of that view. Our scanner prices every CAPR straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a CAPR straddle into a catalyst or short a CAPR straddle to harvest decay, the options straddle setups that matter are all in one place.
| Jan 21, 2028 | 60.00 | $54.20 | 491 | 64% | 77.8% | $114.20 | $5.80 | 7 |
| Jan 21, 2028 | 50.00 | $44.45 | 491 | 64% | 77.5% | $94.45 | $5.55 | 0 |
| Jan 21, 2028 | 32.00 | $27.53 | 491 | 64% | 75.2% | $59.53 | $4.48 | 4 |
| Jan 21, 2028 | 30.00 | $25.60 | 491 | 64% | 75.2% | $55.60 | $4.40 | 6 |
| Jan 21, 2028 | 25.00 | $21.55 | 491 | 64% | 71.6% | $46.55 | $3.45 | 44 |
| Jan 21, 2028 | 27.00 | $23.85 | 491 | 64% | 69.6% | $50.85 | $3.15 | 1 |
| Jan 21, 2028 | 23.00 | $20.05 | 491 | 64% | 69.0% | $43.05 | $2.95 | 21 |
| Jan 21, 2028 | 20.00 | $17.50 | 491 | 64% | 66.6% | $37.50 | $2.50 | 1 |
| Jan 15, 2027 | 60.00 | $51.38 | 120 | 64% | 65.2% | $111.38 | $8.63 | 0 |
| Jan 15, 2027 | 50.00 | $42.00 | 120 | 64% | 62.5% | $92.00 | $8.00 | 1 |
As of September 18, 2026
Find the right straddle before volatility moves
Track CAPR straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→